Journal
IMMUNITY
Volume 43, Issue 5, Pages 959-973Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2015.10.014
Keywords
-
Categories
Funding
- International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Consortium (NAC) [SFP2120/2121]
- Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) [UM1AI100663]
- Bill and Melinda Gates Foundation Collaboration
- American people through USAID
- James and Jessie Minor Chair in Immunology
Ask authors/readers for more resources
Broadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) trimer isolated from individual HIV-infected donors potently neutralize diverse HIV strains, but strategies for designing immunogens to elicit bnAbs have not been identified. Here, we compared four prototypes (PG9, CH01, PGT145, and CAP256.VRC26.09) of V2 apex bnAbs and showed that all recognized a core epitope of basic V2 residues and the glycan-N160. Two prototype bnAbs were derived from VH-germlines that were 99% identical and used a common germline D-gene encoded YYD-motif to interact with the V2-epitope. We identified isolates that were neutralized by inferred germline (iGL) versions of three of the prototype bnAbs. Soluble Env derived from one of these isolates was shown to form a well-ordered Env trimer that could serve as an immunogen to initiate a V2-apex bnAb response. These studies illustrate a strategy to transition from panels of bnAbs to vaccine candidates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available